Exelixis, Inc. (EXEL) stock price, news, quote and history
This article provides a detailed overview of Exelixis, Inc. (EXEL), an oncology company. It includes current stock performance, key financial data such as market cap and P/E ratio, and an overview of its drug pipeline and collaborations. The company's historical performance, earnings trends, and analyst insights are also presented.
Exelixis, Inc. Podcast | EXEL Podcasts & Related Content
This page provides an overview of Exelixis, Inc. (EXEL) including its current stock price, market capitalization, and various financial metrics. It also offers quick links to news, earnings calls, financial data, and podcast content related to the company. The content explicitly states that the information provided is for reference only and does not constitute investment advice.
Exelixis stock hits all-time high at 59.73 USD By Investing.com
Exelixis Inc. (EXEL) stock reached an all-time high of $59.73, reflecting a 44.78% increase over the past year and a 36.75% return in the last six months. Despite strong performance and a promising drug pipeline, an InvestingPro analysis suggests the stock might be overvalued. The company recently surpassed Q2 2026 earnings expectations, though revenue slightly missed forecasts, and the FDA extended its review for zanzalintinib's new drug application.
(EXEL) Volatility Zones as Tactical Triggers
This article analyzes Exelixis Inc. (NASDAQ: EXEL) using AI models to provide tactical triggers based on volatility zones. It highlights a near-term strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward short setup. The analysis includes institutional trading strategies tailored for different risk profiles, offering entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies.
Exelixis stock hits all-time high at 59.73 USD
Exelixis Inc. (NASDAQ:EXEL) stock has reached an all-time high of $59.73, marking a significant 44.78% increase over the past year and a 36.75% return in the last six months. Despite this strong performance, an InvestingPro analysis suggests the stock may be overvalued. Recent developments include exceeding Q2 2026 earnings expectations, though revenue slightly missed estimates, and the FDA extending the review for its new drug zanzalintinib.
Return on equity % of Exelixis, Inc. – HAN:EX9
This article provides a financial data point for Exelixis, Inc. (HAN:EX9) regarding its Return on Equity (ROE) percentage. The content indicates that the specific value for this metric is displayed within a "Period Value Change Change %" section, though the actual figures are not visible in the provided text.
Exelixis stock hits all-time high at 59.73 USD By Investing.com
Exelixis (EXEL) stock has reached an all-time high of $59.73, marking a 44.78% increase over the past year and a 36.75% return in the last six months. Despite this surge, InvestingPro analysis suggests the stock might be overvalued. The company recently reported Q2 2026 earnings that beat EPS expectations but slightly missed revenue forecasts, and the FDA extended the review for its new drug zanzalintinib.
Cash flow from investing activities of Exelixis, Inc. – HAN:EX9
This article focuses on the cash flow from investing activities for Exelixis, Inc. (HAN:EX9). It provides a brief overview of the company's financial data, specifically highlighting its investing cash flow. The content itself is very minimal, serving primarily as a title and indicating where to find financial details.
Exelixis stock hits all-time high at 59.73 USD By Investing.com
Exelixis Inc. stock has reached an all-time high of $59.73, marking a 44.78% increase over the past year and a 36.75% return in the last six months. Despite a strong market performance driven by robust financial results and a promising drug pipeline, InvestingPro analysis suggests the stock may be overvalued. The company recently surpassed Q2 2026 earnings expectations but fell slightly short on revenue, and the FDA extended the review period for its new drug zanzalintinib.
Exelixis stock hits all-time high at 59.73 USD By Investing.com
Exelixis stock reached an all-time high of $59.73, marking a 44.78% increase over the past year. The company's growth is attributed to strong financial results and a promising drug pipeline, despite some InvestingPro analysis suggesting it may be overvalued. Recent developments include exceeding Q2 2026 adjusted EPS expectations, but slightly missing revenue forecasts and experiencing an FDA extension for a new drug application.
Exelixis, Inc. (EXEL) Stock forecasts
Argus has raised its target price for Exelixis, Inc. (EXEL) to $64.00, with the biopharmaceutical firm currently trading at $58.84. Exelixis specializes in discovering, developing, and commercializing cancer treatments. The report was issued on September 23, 2026.
How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension
The FDA extended its review of Exelixis' zanzalintinib plus atezolizumab NDA for metastatic colorectal cancer by three months, pushing the PDUFA date to March 3, 2027. This extension, while delaying a key catalyst, allows regulators to review a more mature dataset and influences the company's efforts to build a second oncology franchise around zanzalintinib alongside cabozantinib. Investors are now focused on execution quality, regulatory clarity, and managing R&D within stated limits.
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Exelixis' investigational cancer drug, zanzalintinib, faces a three-month delay in FDA review for its New Drug Application (NDA) for metastatic colorectal cancer, pushing the target action date to March 3, 2027. This setback follows the FDA's request for additional information and subsequent classification of Exelixis' submission of updated data as a major amendment. The delay impacts Exelixis' plans to diversify its oncology portfolio and build a second commercial franchise, though the company continues to advance zanzalintinib in other collaborations and studies.
Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer
Exelixis (EXEL) announced that the FDA has extended its review period for zanzalintinib plus atezolizumab for metastatic colorectal cancer after the company submitted new safety and efficacy data. This extension, while causing a delay, is seen as an opportunity for Exelixis to strengthen the regimen's position as a durable treatment option. The company aims to diversify its oncology portfolio beyond cabozantinib, with zanzalintinib being a key component in its future growth strategy.
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
Exelixis (EXEL) announced a three-month extension for the FDA's review of zanzalintinib, pushing the target action date to March 3, 2027. The extension followed a major amendment submission with updated safety and efficacy data. The article discusses the bull and bear cases for approval, highlighting the positive overall-survival in the full STELLAR-303 study population versus the lack of statistical significance in a specific subgroup and treatment burden.
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
Exelixis (EXEL) has announced a three-month extension of the FDA's review for its drug zanzalintinib, setting a new target action date of March 3, 2027. This extension, due to an FDA request for updated safety and efficacy information classified as a major amendment, leaves the drug's approval unresolved. The article discusses the bull and bear cases for zanzalintinib's approval, highlighting a positive overall survival benefit in the full study population against concerns about a subgroup analysis and increased treatment burden.
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
Exelixis (NASDAQ: EXEL) saw its stock slip after the FDA extended the review period for its cancer drug zanzalintinib by three months. The delay, attributed to Exelixis submitting updated safety and efficacy data, pushed the Prescription Drug User Fee Act action date to March 3, 2027. Despite the short-term market volatility, analyst Andy Hsieh from William Blair believes the risk of rejection remains low and the long-term revenue potential for zanzalintinib should not be significantly diminished.
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months
Exelixis (NASDAQ:EXEL) shares dropped 3.5% after the FDA extended the review period for its new drug application for zanzalintinib by three months. The extension, triggered by the company's submission of updated safety and efficacy data, pushes the Prescription Drug User Fee Act action date to March 3, 2027. Zanzalintinib is being evaluated in combination with atezolizumab for metastatic colorectal cancer.
FDA extends review of Exelixis drug application for metastatic colorectal cancer
The FDA has extended its review period by three months for Exelixis's new drug application (NDA) for zanzalintinib in combination with atezolizumab, intended for metastatic colorectal cancer. This extension, due to new safety and efficacy data, pushes the PDUFA action date to March 3, 2027. Despite this regulatory delay, Exelixis's stock remains strong, trading near its 52-week high, with analysts showing confidence in the company's broader pipeline.
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Adagene Inc. announced a significant milestone in its collaboration with Exelixis, Inc., receiving a $2.0 million payment for a preclinical milestone related to XB404, an antibody-drug conjugate built with Adagene's SAFEbody masking technology. An additional payment was triggered by the selection of candidates for another SAFEbody® ADC program. Exelixis has the right to utilize Adagene's SAFEbody technology platform to develop masked ADC candidates, with Adagene eligible for further milestone payments and royalties.
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) has seen its shares rise 13.3% since its last earnings report, outperforming the S&P 500. The company reported strong Q2 adjusted EPS, beating estimates, though revenue missed expectations. Despite lowering its 2026 revenue outlook due to a slower-than-projected ramp-up in a neuroendocrine tumor indication, Exelixis continues to advance its zanzalintinib pipeline and share repurchase program.
Exelixis stock hits all-time high at 57.68 USD
Exelixis Inc. stock has reached an all-time high of $57.68, marking a significant 53% increase over the past year. Despite analyst upgrades, InvestingPro's Fair Value analysis suggests the stock might be overvalued. The company's CABOMETYX franchise continues to drive revenue, though full-year guidance was revised down due to slower growth in its NET business.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2026
Exelixis, Inc. announced that its management will participate in webcasted fireside chats at three investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference on September 8, the Citi 2026 Biopharma Back to School Conference on September 9, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The presentations will be accessible via webcast on the company's website under the Investors & News section, with replays available for at least 30 days. Exelixis is an oncology company focused on developing next-generation cancer treatments, including its flagship product CABOMETYX® and its novel oral kinase inhibitor zanzalintinib.
Exelixis Wins Appeal in Patent Case Against MSN Laboratories
Exelixis has won an appeal in a patent case against MSN Laboratories. The article, published on August 31, 2026, reports on this legal victory without providing further details on the case itself. It also briefly mentions other recent news for Exelixis, including its Q2 2026 earnings call and revenue guidance.
Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition
Exelixis (EXEL) is increasing shareholder value through significant share buybacks, funded by the strong performance of its oncology drug, CABOMETYX. Despite a recent cut in revenue guidance, the company's free cash flow remains stable, supporting its buyback program. The future growth largely depends on the regulatory approval of its next potential franchise drug, zanzalintinib, which awaits a decision in December 2026.
BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL
BlackRock Inc. has acquired a new 29.1 million-share stake in Exelixis (NASDAQ:EXEL), valued at approximately $1.58 billion, representing 11.57% of the biotechnology company. Institutional investors now own 85.27% of EXEL, which recently reported strong quarterly earnings of $0.91 EPS, beating estimates, though revenue was slightly below expectations. Despite insiders selling shares, analysts generally maintain a "Hold" rating with an average price target of $50.07 for Exelixis.
NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL
NFJ Investment Group LLC has acquired a new stake of 338,045 shares in Exelixis, Inc. (NASDAQ:EXEL) worth approximately $18.39 million during the second quarter, bringing institutional ownership in the biotechnology company to 85.27%. This investment comes as Exelixis reported strong quarterly earnings, beating analyst estimates with $0.91 EPS and 10.6% year-over-year revenue growth. Despite a "Hold" consensus rating, analysts have recently raised price targets, reflecting a mixed but generally optimistic outlook for the company whose stock opened near its 52-week high.
51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC
NewEdge Wealth LLC acquired a new stake of 51,642 shares in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, valued at approximately $2.81 million. Several other institutional investors also made new investments in the biotechnology company. Exelixis recently reported strong quarterly earnings, beating analyst estimates, and has an average "Hold" rating from analysts with an average price target of $50.07.
Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXEL
Abacus FCF Advisors LLC has acquired a new stake worth approximately $7.29 million in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, bringing their total ownership to 0.05% of the biotechnology company. Other institutional investors like BlackRock Inc., AQR Capital Management LLC, Norges Bank, and Bank of New York Mellon Corp also made significant investments, while some insiders sold shares. Analyst ratings for Exelixis currently lean towards a "Hold" with a consensus price target of $50.07.
Out of sight, out of work? What’s driving remote job cuts
Some biopharma companies are reducing their remote workforce, forcing employees to choose between returning to the office, relocating, or resigning, as seen with EMD Serono and Exelixis. While many employers cite collaboration benefits for requiring on-site presence, other factors like program cuts or cost reductions also drive layoffs, affecting both remote and on-site staff. Experts suggest that job security remains a general industry risk, regardless of work location, though some candidates are wary of changing remote work policies.
Investigation launched into EXELIXIS officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into whether certain officers and directors of EXELIXIS, Inc. breached their fiduciary duties through potential self-dealing. This probe could result in shareholder damages and calls for corporate governance reforms. Long-term EXEL shareholders are advised to contact the law firm for a free consultation to protect their rights.
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders, focusing on potential self-dealing. Long-term EXEL stockholders are encouraged to contact the firm for a free consultation to explore potential damages and corporate governance reforms, as participation helps maintain the integrity of financial markets.
EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54
BMO has initiated coverage on Exelixis Inc. (EXEL.O) with a "Market Perform" rating. The firm has set a price target of $54 for the biotechnology company. This information was reported by Reuters.
JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL
JLB & Associates Inc. has purchased 48,849 shares of Exelixis, Inc. (NASDAQ:EXEL) for approximately $2.66 million, marking a new position in the biotechnology company. Institutional investors and hedge funds collectively own a significant 85.27% of Exelixis, which recently reported strong quarterly earnings exceeding estimates, though revenue was slightly below expectations. Despite mixed analyst sentiment resulting in an average "Hold" rating, the company's stock has seen positive movement, while insiders have sold a portion of their holdings.
BMO initiates Exelixis stock at Market Perform, cites patent cliff
BMO Capital initiated coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and a $54.00 price target, citing concerns about a patent cliff in early 2030 for its main drug, cabozantinib. While the company's financial health is strong, BMO remains cautious as the follow-up drug, zanzalintinib, is not fully de-risked and its potential revenue may not offset the decline from cabozantinib. This comes despite Exelixis recently beating earnings estimates but lowering its full-year revenue guidance.
Pallas Capital Advisors LLC Invests $1.67 Million in Exelixis, Inc. $EXEL
Pallas Capital Advisors LLC has invested $1.67 million in Exelixis, Inc. by purchasing 30,721 shares in the second quarter. Institutional investors and hedge funds collectively own a significant 85.27% of the biotechnology company's stock. Exelixis recently reported strong quarterly earnings, beating EPS estimates, and has an average "Hold" rating from analysts with a consensus price target of $49.79.
27,109 Shares in Exelixis, Inc. $EXEL Purchased by Grandfield & Dodd LLC
Grandfield & Dodd LLC has acquired 27,109 shares of Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, valued at approximately $1.48 million. This purchase contributes to the 85.27% of the stock already owned by institutional investors. Despite the company beating earnings estimates with $0.91 per share, revenue fell slightly short of expectations at $628.69 million, though it marked a 10.6% year-over-year increase.
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky is investigating Exelixis (NASDAQ: EXEL) following a revenue miss in its second-quarter report, which caused shares to decline by approximately 7.9%. The company reported $628.7 million in revenue, below analyst consensus, and also lowered its full-year 2026 revenue outlook due to a slower-than-expected ramp in its neuroendocrine-tumor business. Shareholders who suffered losses are encouraged to contact the firm for a review of their claim.
Focus Partners Advisor Solutions LLC Buys Shares of 26,603 Exelixis, Inc. $EXEL
Focus Partners Advisor Solutions LLC initiated a new position in Exelixis, Inc. by purchasing 26,603 shares valued at approximately $1,447,000 during the second quarter. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., Goldman Sachs Group Inc., and Sivia Capital Partners LLC also adjusted their holdings in the biotechnology company. Exelixis reported strong Q2 earnings, beating analyst estimates, and has a current market capitalization of $12.70 billion.
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by Exelixis, Inc. (NASDAQ: EXEL) after the company missed Q2 revenue estimates and lowered its full-year 2026 revenue guidance. The investigation focuses on whether Exelixis made false or misleading statements to investors, particularly concerning its neuroendocrine-tumor business for CABOMETYX. SBS encourages shareholders who suffered losses to participate in the investigation.
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Exelixis, Inc. (NASDAQ: EXEL) following the company missing Q2 revenue estimates and lowering its full-year 2026 revenue guidance. The investigation focuses on whether Exelixis made false or misleading statements to investors, particularly regarding its neuroendocrine-tumor business and the market position of CABOMETYX. SBS is inviting shareholders who have incurred losses to join the fraud investigation.
Exelixis (EXEL) Is Down 5.2% After Raising Q2 Profitability And Trimming 2026 Revenue Outlook – Has The Bull Case Changed?
Exelixis recently reported its Q2 2026 results, showing increased profitability but a slight reduction in its full-year 2026 revenue outlook to US$2.50 billion–US$2.55 billion. Despite the revenue trim, the core investment narrative remains focused on diversifying beyond cabozantinib through its oncology pipeline, with the December 2026 PDUFA decision for zanzalintinib being a key near-term catalyst. The revised guidance slightly tightens the gap between consensus expectations and more bullish scenarios, prompting investors to assess the company's transition strategy.
Farallon Capital (EXEL) discloses 13.99M-share Exelixis stake at $308M cost
Farallon Capital Management, L.L.C., and its affiliated investment partnerships, the Farallon Funds, have disclosed a beneficial ownership of 13,989,010 shares of Exelixis, Inc. (EXEL). This stake represents 5.6% of Exelixis' outstanding common stock and has an approximate net investment cost of $308,124,978. The information was reported in an amended Schedule 13D filing, which details the various entities and individuals exercising shared voting and dispositive power over these shares, all acquired through open-market transactions.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)
Levi & Korsinsky, LLP is investigating potential securities law violations concerning Exelixis (EXEL) after the company's Q2 revenue of $628.7 million missed Wall Street expectations, despite an adjusted EPS beat of $0.91. Investors who purchased EXEL and suffered losses are encouraged to contact the firm for a free case evaluation regarding potentially false or misleading statements about the company's commercial performance.
Exelixis Inc (EXEL) Director Mary Beckerle Sells 9,812 Shares
Exelixis Inc (EXEL) Director Mary Beckerle recently sold 9,812 shares for approximately $526,500, continuing a trend of insider selling with 22 insider sells against only 1 insider buy over the past year. The stock is considered modestly overvalued by GuruFocus's GF Value at $53.66, against a fair value of $45.58, despite its P/E ratio being lower than the industry median. This insider activity and valuation, along with more gurus trimming positions, suggest caution for investors.
Exelixis (EXEL) Q2 2026 Earnings Call Transcript
Exelixis (EXEL) reported its Q2 2026 earnings, with total revenues reaching $628.7 million, a 10.6% increase year-over-year, driven by cabozantinib sales. The company updated its full-year 2026 revenue guidance downwards due to a more gradual sales ramp in the neuroendocrine tumor indication but reduced R&D expense guidance to maintain capital discipline. Exelixis is focusing on developing zanzalintinib as its next franchise molecule, with several pivotal trials underway and a PDUFA date for zanza plus atezolizumab in metastatic colorectal cancer set for December 3, 2026.
Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL
Annex Advisory Services LLC has acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL), purchasing 25,918 shares valued at approximately $1.41 million during the second quarter. This investment comes as Exelixis reported strong quarterly earnings, surpassing EPS expectations, though revenue slightly missed analyst estimates. Despite significant insider selling over the past 90 days, institutional investors collectively hold a substantial 85.27% of the company, and analysts maintain a consensus "Hold" rating with an average price target just below the stock's opening price.
Exelixis, Inc. (EXEL) Stock Forecasts
Argus has lowered its target price for Exelixis Inc. (EXEL) to $56.00, while the current price stands at $50.44. Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments.
Exelixis director Mary Beckerle sells $526k in shares
Exelixis director Mary C. Beckerle sold 9,812 shares of the company's common stock for $526,511 on August 10, 2026, under a Rule 10b5-1 trading plan. Following the sale, she beneficially owns 16,079 shares, including RSUs. This transaction occurred amidst a recent 3.5% stock drop, though shares have returned 31% over the past year, while the company reported mixed Q2 2026 financial results with an earnings beat but a downward revision of full-year revenue guidance.
Exelixis director Mary Beckerle sells $526k in shares
Exelixis director Mary Beckerle sold 9,812 shares of the company's common stock for over $526,000, executed under a Rule 10b5-1 trading plan. This transaction leaves her with 16,079 beneficially owned shares, including RSUs. The sale occurred as Exelixis's stock saw a recent decline but maintained a strong annual return, with InvestingPro suggesting the stock is currently undervalued.
